

Dear Dr. Dou,

Many thanks for reviewing our manuscript INO: 00112071 entitled "Vedolizumab in combined immune related infliximab-refractory colitis: A case report and review of literature". We have addressed the comments below and the attached manuscript has additions highlighted in yellow.

Kind regards,

Professor Desmond Yip
Clinical Director, Department of Medical Oncology
The Canberra Hospital
Yamba Drive | Garran, ACT 2606 Australia
tel +612 5124 2220 mobile +614 38868036 fax +612 5124 4266

Reviewer(s)' Comments to Author:

- 1) **Please revise the manuscript according to the review report and my comments. And answer all of the reviewers' comments carefully (point-to-point).**

Please see below.

- 2) **Our policy for the Case Report manuscript requires the title to include the disease name, the number of cases, and the phrase "literature review". In addition, the description of the paper as a literature review must be supported by the manuscript's content. Please update the reference list and add references with accompanying textual content that will strengthen the manuscript as a literature review of the appropriate and up-to-date case-related information. Please note that if authors only add the words "literature review" to the title, but do not revise the textual content of the manuscript to provide a literature review, the manuscript will be rejected.**

The title has now been changed to "Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report and literature review" and a literature review has been done including manuscripts published recently. [We have also described our search methodology.](#)

- 3) **Please provide the author contributions. See the format in the attachment file-revision policies. The format of this section should be like this: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed research; Wang CL, Zou CC, Hong F and Wu XM performed research; Xue Jz and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed data; and Wang CL, Liang L and Fu JF wrote the paper.**

The following has now been added:

Author contributions: Randhawa M, Gaughran G and Archer C contributed equally to this work and wrote the paper; Randhawa M, Gaughran G, Archer C, Pavli P, Ali S and Yip D were involved in care of this patient and review and revision of this paper.

- 4) **Please make an audio record of your core tip. The accepted formats are: mp3/wma.**

This has now been added and attached.

- 5) **Please check and confirm that there are no repeated references!**

This has now been reviewed and corrected.

- 6) **Please provide the decomposable figure of Figures, whose parts are movable and editable. So you can put the original pictures in PPT and submit it in the system.**

This has now been attached as a separate file

- 7) **Please provide the decomposable figure of Figures, whose parts are movable and editable. So you can put the original pictures in PPT and submit it in the system.**

This has now been attached as a separate file

- 8) **Please provide the decomposable figure of Figures, whose parts are movable and editable. So you can put the original pictures in PPT and submit it in the system.**

This has now been attached as a separate file